- Home
- STG vs IMUX Comparison
STG vs IMUX Comparison
Compare STG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- IMUX
- Stock Information
- Founded
- STG 2003
- IMUX 2016
- Country
- STG China
- IMUX United States
- Employees
- STG N/A
- IMUX N/A
- Industry
- STG Other Consumer Services
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- IMUX Health Care
- Exchange
- STG Nasdaq
- IMUX Nasdaq
- Market Cap
- STG 108.2M
- IMUX 110.8M
- IPO Year
- STG 2018
- IMUX N/A
- Fundamental
- Price
- STG $6.70
- IMUX $1.06
- Analyst Decision
- STG
- IMUX Strong Buy
- Analyst Count
- STG 0
- IMUX 5
- Target Price
- STG N/A
- IMUX $13.20
- AVG Volume (30 Days)
- STG 7.7K
- IMUX 1.5M
- Earning Date
- STG 11-22-2024
- IMUX 11-07-2024
- Dividend Yield
- STG N/A
- IMUX N/A
- EPS Growth
- STG N/A
- IMUX N/A
- EPS
- STG 4.83
- IMUX N/A
- Revenue
- STG $286,479,516.00
- IMUX N/A
- Revenue This Year
- STG N/A
- IMUX N/A
- Revenue Next Year
- STG N/A
- IMUX N/A
- P/E Ratio
- STG $1.39
- IMUX N/A
- Revenue Growth
- STG N/A
- IMUX N/A
- 52 Week Low
- STG $4.25
- IMUX $0.97
- 52 Week High
- STG $12.55
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- STG 44.80
- IMUX 28.31
- Support Level
- STG $6.65
- IMUX $1.15
- Resistance Level
- STG $6.98
- IMUX $1.28
- Average True Range (ATR)
- STG 0.30
- IMUX 0.08
- MACD
- STG -0.01
- IMUX -0.01
- Stochastic Oscillator
- STG 18.52
- IMUX 12.90
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.